Skip to main content

letter

. 1990 Mar;61(3):491. doi: 10.1038/bjc.1990.108

Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2)

C J Punt, S C Henzen-Logmans, R L Bolhuis, G Stoter

PMCID: PMC1971290 PMID: 2328219

491

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Hancock W. W., Muller W. A., Cotran R. S. Interleukin 2 receptors are expressed by alveolar macrophages during pulmonary sarcoidosis and are inducible by lymphokine treatment of normal human lung macrophages, blood monocytes, and monocyte cell lines. J Immunol. 1987 Jan 1;138(1):185–191. [PubMed] [Google Scholar]
Matory Y. L., Chang A. E., Lipford E. H., 3rd, Braziel R., Hyatt C. L., McDonald H. D., Rosenberg S. A. Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. J Biol Response Mod. 1985 Aug;4(4):377–390. [PubMed] [Google Scholar]
West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES